August 6th 2025
Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Dr Blase Polite Outlines the Decision to Move to 2-Sided Risk in the OCM
Dr James Hamrick Discusses Bringing Value to Patients Through Engagement
Lessons From the Field: How Practices Are Succeeding Under OCM
Mike Fazio: Practices Are Happier With PP4 Results in the OCM